BioSpace News Archive

Evelo Biosciences, Inc. today announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis.

uniQure N.V. today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.

Akouos, Inc. presented nonclinical data at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting that support future development of gene therapies targeting inner ear conditions.

Nanoscope Therapeutics today announced full enrollment of its Phase 2b clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in patients with retinitis pigmentosa (RP).

Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ET.

Orchard Therapeutics, a global gene therapy leader, outlined five upcoming presentations from across its neurodegenerative portfolio to be featured at the 18th Annual WORLDSymposium™ being held on February 7-11, 2022.

Amicus Therapeutics, a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced that two oral presentations and 11 posters across its development programs will be included at the 18th Annual WORLDSymposium™ 2022, being held February 7-11, 2022 in San Diego, CA.

Calyxt, Inc. today announced that Gerry Nuovo has joined Calyxt as Senior Vice President of Business Development.

Evogene Ltd. announced today that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25th at 9:00 Eastern.